Inhibitory Effect of Alendronate on Bone Resorption of Autogenous Free Bone Grafts in Rats

Journal of Oral and Maxillofacial Surgery

Volumn 65, Issue 3, 2007, Pages 508-516

  Altundal, Hatice ^a   Sayrak, Hakan ^b   Yurtsever, Ertuǧrul ^c   Göker, Kamil ^c  

^a YEDITEPE UNIVERSITY   (Turkey)

^b Dr Pakize i Tarzi Laboratuarlari Turkey   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; DIHYDROXYCOLECALCIFEROL; PARATHYROID HORMONE; PHOSPHATE; PYRIDINOLINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; BONE GRAFT; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIET RESTRICTION; FEMUR; HISTOPATHOLOGY; INHIBITION KINETICS; MALE; NONHUMAN; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; RAT; URINALYSIS;

EID: 33847326378     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2005.11.054     Document Type: Article

References (62)

1. van Steenberghe D., Naert I., Bossuyt M., et al. The rehabilitation of the severely resorbed maxilla by simultaneous placement of autogenous bone grafts and implants: A 10-year evaluation. Clin Oral Invest 1 (1997) 102
2. Myoung H., Park J.Y., and Choung P.H. Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. J Periodontol Res 36 (2001) 244
3. Gosain A.K., Song L., Santoro T.D., et al. Long-term remodeling of vascularized and nonvascularized onlay bone grafts: A macroscopic and microscopic analysis. Plast Reconstr Surg 103 (1999) 1443
4. Ukai T., Hara Y., and Kato I. Effects of T cell adoptive transfer into nude mice on alveolar bone resorption induced by endotoxin. J Periodont Res 31 (1996) 414
5. Votta B.J., Levy M.A., Badger A., et al. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J Bone Miner Res 12 (1997) 1396
6. Gazdag A.R., Lane J.M., Glaser D., et al. Alternatives to autogenous bone graft: Efficacy and indications. J Am Acad Orthop Surg 3 (1995) 1
7. Gordt M., and Alberius P. Some basic factors essential to autogeneic nonvascularized onlay bone grafting to the craniofacial skeleton. Scand J Plast Reconstr Hand Surg 33 (1999) 129
8. Siris E., Weinstein R.S., Altman R., et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 81 (1996) 961
9. Lafage M.H., Balene R., Battle M.A., et al. Comparison of alendronate and sodium fluoride effect on cancellous and cortical bone in minipigs. J Clin Invest 95 (1995) 2127
10. Boivin G., and Meunier P.J. Effects of bisphosphonates on matrix mineralization. J Musculoskel Neuron Interact 2 (2002) 538
11. Fleich H. Bisphosphonates in osteoporosis: An introduction. Osteoporosis Int 3 (1993) 3
12. Owens J.M., Fuller K., and Chambers T.J. Osteoclast activation: Potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism. J Cell Physiol 172 (1997) 79
13. Levin L., Bryson E.C., Caplan D., et al. Effect of topical alendronate on root resorption of dried replanted dog teeth. Dent Traumatol 17 (2001) 120
14. Kaynak D., Meffert R., Günhan M., et al. A histopathological investigation on the effects of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the mandible of rats. J Periodontol 71 (2000) 790
15. Weinreb M., Quartuccio H., Seedor J.G., et al. Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodont Res 29 (1994) 35
16. El-Shinnawi U.M., and El-Tantawy S.I. The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial). J Int Acad Periodontol 5 (2003) 5
17. Binderman I., Adut M., and Yaffe A. Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats. J Periodontol 71 (2002) 1236
18. Yaffe A., Izitkovich M., Earon Y., et al. Local delivery of an amino biphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats. J Periodontol 68 (1997) 884
19. Reddy M.S., Weatherford T.W., Smith C.A., et al. Alendronate treatment of naturally occurring periodontitis in beagle dogs. J Periodontol 66 (1995) 211
20. Shoji K., Horiuchi H., and Shinoda H. Inhibitory effects of a biphosphonate (risedronate) on experimental periodontitis in rats. J Periodont Res 30 (1995) 277
21. Warita H., Kirino Y., Kurihara S., et al. Effects of local injection with bisphosphonate (HEBT) on experimental tooth movement. J Jpn Orthod Soc 51 (1992) 292
22. Kayou L., Sugiyama H., Imoto S., et al. Effects of bisphosphonate on the remodeling of rat sagittal suture after rapid expansion. Angle Orthod 71 (2001) 265
23. Igarashi K., Mitani H., Adachi H., et al. Anchorage and retentive effects of a bisphosphonate (AHBuBP) on tooth movement in rats. Am J Orthod Dentofac Orthop 106 (1994) 279
24. Igarashi K., Adachi H., Mitani H., et al. Inhibitory effect of the topical administration of a bisphosphonate (Risedronate) on root resorption incident to orthodontic tooth movement in rats. J Dent Res 75 (1996) 1644
25. Aspenberg P., and Astrand J. Bone allografts pretreated with a bisphosphonate are not resorbed. Acta Orthop Scand 73 (2002) 20
26. Gosain A.K., McCarthy J.G., Staffenberg D., et al. The histomorphologic changes in vascularized bone transfer and their interrelationship with the recipient sites: A 1-year study. Plast Reconstr Surg 97 (1996) 1001
27. Kahnberg K.E., Rasmusson L., and Mohammad S. An experimental study rabbit model for studying the healing of onlay bone grafts. Swed Dent J 22 (1998) 15
28. de Koomen H.A., Stoelinga P.J.W., Tideman H., et al. Interposed bone graft augmentation of the atrophic mandible. J Maxillofac Surg 7 (1979) 129
29. Stoelinga P.J.W., Tideman H., Belger J.S., et al. Interpositional bone graft augmentation of the atrophic mandible. A preliminary report. J Oral Surg 36 (1978) 30
30. Zabka A.G., Pluhar G.E., Edwards R.B., et al. Histomorphometric description of allograft bone remodeling and union in a canine segmental femoral defect model: A comparison of rhBMP-2, cancellous bone graft, and absorbable collagen sponge. J Orthop Res 19 (2001) 318
31. Johanson B., Grepe A., Wannfors K., et al. A clinical study of changes in the volume of bone grafts in the atrophic maxilla. Dentomaxillofac Radiol 30 (2001) 157
32. Gordt M., and Alberius P. Some basic factors essential to autogeneic nonvascularized onlay bone grafting to the craniofacial skeleton. Scand J Plast Reconstr Hand Surg 33 (1999) 129
33. Bettica P., Bevilacqua M., Vago T., et al. Short-term variations in bone remodeling biochemical markers: Cyclical etidronate and alendronate effects compared. J Clin Endocrinol Metab 82 (1997) 3034
34. Garnero P., Shih W.J., Gineyts E., et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79 (1994) 1693
35. Jeal W., Barradell L.B., and Mctavish D. Alendronate: A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Drugs 53 (1997) 415
36. Sass D.A., Bowman A.R., Yuan Z., et al. Alendronate prevents cyclosporin A induced osteopenia in the rat. Bone 21 (1997) 65
37. Khan S.A., Vasikaran S., McCloskey E.V., et al. Alendronate in the treatment of Paget's disease of bone. Bone 20 (1997) 263
38. Rodan J.A., and Fleisch H.A. Bisphosphonate: Mechanism of action. J Clin Invest 97 (1996) 2692
39. Nancollas G.H., Mangood A.H., Gaafar E.M., et al. Mineral binding affinities of bisphosphonates. Bone 30 (2002) 42
40. Roschger P., Fratzl P., Klaushofer K., et al. Mineralization of cancellous bone after alendronate and sodium fluoride treatment: A quantitative backscattered electron imaging study on minipig ribs. Bone 20 (1997) 393
41. Balena R., Markatos A., Seedor J.G., et al. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae. J Pharmacol Exp Ther 276 (1996) 277
42. Weinstein R.S., Chen J.R., Powers C.C., et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109 (2002) 1041
43. Van Beek E.R., Löwik C.W.G.M., and Papalous S.E. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 30 (2002) 64
44. McClung M.R. Bisphosphonates. Endocrinol Metab Clin North Am 32 (2003) 253
45. Dunford J.E., Ebetino F.H., and Rogers M.J. The mechanism of inhibition of farnesyl disphosnate synthase by nitrogen-containing bisphosphonates. Bone 30 (2002) 40
46. 3H-Etidronate in rat and mouse bones. Bone 19 (1996) 281
47. Van Beek E.R., Löwik C.W.G.M., and Papapoulos S.E. Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice. Bone 20 (1997) 335
48. Hughes D.E., Wright K.R., Uy H.L., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10 (1995) 1478
49. Frolik C.A., Bryant H.U., Black E.C., et al. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effect of raloxifene HCI, tamoxifen, estrogen, and alendronate. Bone 18 (1996) 621
50. Tucci J.R., Tonino R.P., Emkey R.D., et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101 (1996) 488
51. Harris S.T., Gertz B.J., Genant H.K., et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76 (1993) 1399
52. Eriksen E.F., Melsen F., Sod E., et al. Effects of long-term Risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31 (2002) 620
53. McClung M.R. Current bone mineral density data on bisphosphonate in postmenopausal osteoporosis. Bone 19 (1996) 195
54. Yaffe A., Kollerman R., Bahar H., et al. The influence of alendronate on bone formation and resorption in a rat ectopic bone development model. J Periodontol 74 (2003) 44
55. Rossini M., Gatti D., Zamberlan N., et al. Long-term effects of a treatment course with oral alendronate on postmenopausal osteoporosis. J Bone Miner Res 9 (1994) 1833
56. Hu J.H., Ding M., Soballe K., et al. Effects of short-term alendronate treatment on the three-dimensional microstructural, physical, and mechanical properties of dog trabecular bone. Bone 31 (2002) 591
57. Meraw S.J., and Reeve C.M. Qualitative analysis of peripheral peri-implant bone and influence of alendronate sodium on early bone regeneration. J Periodontol 70 (1999) 1228
58. Mashiba T., Hirano T., Turner C.H., et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15 (2000) 613
59. Liberman U.A., Weiss S.R., Broll J., et al. Effects of oral alendronate on bone mineral density and incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333 (1995) 1437
60. Reid I.R., Brown J.P., Burckhardt P., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346 (2002) 653
61. Kanis J.A., Gertz B.J., Sibger F., et al. Rationale for the use of alendronate in osteoporosis. Osteoporos Int 5 (1995) 1
62. Ravn P., Neugebauer G., and Christiansen C. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone 30 (2002) 320